Cantor Fitzgerald restated their buy rating on shares of CymaBay Therapeutics (NASDAQ:CBAY) in a report released on Friday, The Fly reports. Cantor Fitzgerald currently has a $20.00 price target on the biopharmaceutical company’s stock.
“Reiterate our Overweight rating; increasing 12-mo. PT to $20. CymaBay is a liver disease company with lead asset, seladelpar, in Ph3 for primary biliary cholangitis (PBC). Our checks suggest seladelpar’s strong profile in PBC has the potential to grow the market significantly from where it is today. We think the opportunity in PBC alone (~$350M in 2026 unadjusted sales vs. cap of $500M) should justify upside. We see further potential for seladelpar with a 2Q19 Ph2b NASH proof of concept readout, which could be a much larger opportunity (~ $4B+) for Seladelpar if successful. In our 75-page slide deck, we took a close look at PPAR-delta biology & role in NASH. Our Take: PPAR-delta has the potential to be a major target in the NASH space,” the firm’s analyst commented.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.